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Matthew Rimmer 
In July 2014, Melbourne hosted the 20th International AIDS Conference. The event 
opened, paying tribute to the late Dutch HIV/AIDS researcher Professor Joep Lange, 
with his image projected onto a screen, with the accompanying quotation: ‘If we can 
bring a bottle of Coke to every corner of Africa, we should be able to also deliver 
antiretroviral drugs.’ 
Fire in the Blood, Trailer, Documentary 
https://www.youtube.com/watch?v=eVf2UUu_w4o 
In the Jonathan Mann memorial lecture, Michael Kirby — a champion of HIV/AIDS law 
reform, and a former Justice of the High Court of Australia — emphasized the need 
to reform intellectual property laws in order to tackle the scourge of HIV/AIDS. He 
has a longstanding interest in the topic. As he wrote in a foreword to a book on 
Intellectual Property and Biotechnology, battles over patents in respect of HIV/AIDS 
research have been waged since the 1980's. Michael Kirby commented in his 
Melbourne speech: 
Without changing the global laws on intellectual property, people will die needlessly. 
It is as simple as that. Someone must tell those who will not act, the practical facts 
of life in our world. They cannot expect taxpayers in other countries to shell out, 
indefinitely, huge funds for antiretroviral drugs if they simply refuse to reform their 
own laws and policies to help their own citizens. 
Michael Kirby stressed that there was a need to value the human right to life-saving 
medicines. He called upon his friend, the Australian Prime Minister, Tony Abbott, to 
show leadership on law reform: ‘As a conviction politician and an unabashed 
conservative, Tony Abbott may be able to help us in this world to reach out to 
those political leaders, at the coming G20 Summit in Brisbane and in the meetings 
of the Commonwealth of Nations, to break the deadly logjam of inaction or wrong 
actions.’ 
Thus far, despite good intentions, Australia has been slow to implement its 
international obligations in respect of access to essential medicines. The Doha 
Declaration 2001 and the WTO General Council Decision 2003 were designed to 
enable countries to make use of flexibilities under the TRIPS Agreement 1994 to 
address public health concerns — such as access to essential medicines in respect 
of HIV/AIDS, tuberculosis, and malaria. In 2013, the House of Representatives in the 
Australian Parliament passed a bill to enable to export of essential medicines to 
developing countries and least developed countries. However, before the Senate 
could debate the bill, Kevin Rudd won a leadership ballot against Julia Gillard, and 
Parliament was prorogued. As a result, the bill lapsed. The Coalition of the Liberal 
Party and the National Party won the ensuing election. 
In 2014, the Coalition Government introduced a new bill, the Intellectual Property 
Laws Amendment Bill 2014 (Cth). To his credit, Bob Baldwin, the Parliamentary 
Secretary to the Minister for Industry, has shown a good understanding of the need 
for legislative action in respect of patent law and access to essential medicines. 
Baldwin emphasized in his second reading speech: 
Schedules 1 and 2 to the Bill amend the Patents Act to implement the Protocol 
amending the World Trade Organization Agreement on Trade-Related Aspects of 
Intellectual Property Rights, also known as the TRIPS Protocol. The Howard 
government accepted the TRIPS Protocol in 2007 and its implementation in Australia 
is well overdue. The TRIPS Protocol helps developing countries that are suffering 
health crises such as malaria, HIV/AIDS and tuberculosis to obtain essential 
medicines from other countries at affordable prices. Millions of people die from 
such diseases every year. At present, elements of our patent system can make it 
harder for Australian businesses to provide assistance to such countries. 
Baldwin noted: ‘To address this, the Bill will enable Australian pharmaceutical 
manufacturers to obtain a licence from the Federal Court to make generic versions 
of patented medicines and to export these medicines to countries with a 
demonstrated need.’ The Parliamentary Secretary stressed: ‘The scheme will ensure 
that patents can only be used under strict conditions and that patent owners are 
fairly compensated.’ Baldwin emphasized: ‘The scheme is also designed to be as 
easy to use as possible, while ensuring appropriate safeguards are in place and 
consistency with Australia’s broader international obligations.’ 
Genevieve Butler of the Australian Parliamentary Library has provided a useful 
overview of the bill. She noted: 
There is international concern that patents should not be used as vehicles for 
healthcare monopolies. For instance, pharmaceutical patents may risk putting 
essential medicines beyond the reach of many people in need of treatment. 
Developing countries often do not have the capacity to manufacture the medicines 
necessary to treat epidemics such as malaria, HIV/AIDS and tuberculosis. The 
interim waiver and the WTO General Council Decision 2003 provide a mechanism to 
supply such countries with the medicines they need to address health epidemics. 
Hopefully, this important legislative reform will be finally passed through the 
Australian Parliament, as a first step to address longstanding issues surrounding 
patent law and access to essential medicines. It is an opportunity for the Prime 
Minister Tony Abbott to demonstrate his leadership in respect of medical research, 
and medical treatment. 
 
Of course, more can and should be done by the Australian Government in respect 
of intellectual property and access to essential medicines. Kirby was a member of 
the Global Commission on HIV and the Law. Chapter 6 of the final 2012 report 
addresses the topic of intellectual property and access to essential medicines. The 
Global Commission on HIV and the Law cites the views of Mohammed El Said and 
Amy Kapczynski: 
Intellectual property policy is a critical component of substantial, continued price 
reductions for ARVs, and of the ability of national governments to extend the 
implications of lessons learned in HIV to other areas of health. The ultimate 
implications, of course, are measured not in technical prose, but in people’s lives. 
The Global Commission on HIV and the Law has a number of recommendations on 
intellectual property and access to essential medicines. First, the Commission asked 
the UN Secretary-General to convene a neutral, high-level body to review and 
assess proposals and recommend a new intellectual property regime for 
pharmaceutical products. The Commission recommended: ‘Such a regime should be 
consistent with international human rights law and public health requirements, while 
safeguarding the justifiable rights of inventors.’ Second, the Commission asked that 
‘high-income countries, including donors such as the United States, European Union, 
the European Free Trade Association countries (Iceland, Liechtenstein, Norway and 
Switzerland) and Japan must immediately stop pressuring low- and middle-income 
countries to adopt or implement TRIPS-plus measures in trade agreements that 
impede access to life-saving treatment.’ 
Third, ‘While the Commission recommends that WTO Members must urgently 
suspend TRIPS as it relates to essential pharmaceutical 
products for low- and middle-income countries, we recognise that such change will 
not happen overnight’. The Commission maintained: ‘In the interim, even though 
individual countries may find it difficult to act in the face of political pressure, they 
should, to the extent possible, incorporate and use TRIPS flexibilities, consistent with 
safeguards in their own national laws.’ Fourth, the Commission argued that ‘The 
WTO Members must indefinitely extend the exemption for Least Developed Countries 
from the application of TRIPS provisions in the case of pharmaceutical products.’ 
Fifth, the Commission observed: ‘The August 30, 2003 Decision of the WTO General 
Council has not proved to be a viable solution for countries with 
insufficient pharmaceutical manufacturing capacity.’ The Commission maintained: ‘It is 
essential that the system established by that decision be 
revised or supplemented with a new mechanism, to allow the easier import of 
pharmaceutical products produced under compulsory licence.’ 
Finally, the Commission noted that ‘TRIPS has failed to encourage and reward the 
kind of innovation that makes more effective pharmaceutical 
products available to the poor, including for neglected diseases.’ The Commission 
commented: ‘Countries must therefore develop, agree and invest in new systems 
that genuinely serve this purpose, prioritising the most promising approaches 
including a new pharmaceutical R&D treaty and the promotion of open source 
discovery.’ 
 
Médecins Sans Frontières (MSF) has been a longstanding champion of access to 
essential medicines. At the Melbourne conference, the Doctors without Borders 
emphasized that there is a need for concerted actions by countries to make HIV 
treatments more affordable. ‘Nearly 12 million people are now receiving antiretroviral 
therapy (ART) in developing countries’, said Dr Jennifer Cohn, Medical Director of 
MSF’s Access Campaign. ‘With people increasingly starting treatment earlier and 
remaining on treatment for life, patients need better-tolerated first-line treatments as 
well as affordable second line-therapy for when first-line medicines fail.’ She 
observed: ‘We know what tools we need to use to help ensure people’s HIV virus 
can get to undetectable and stay there’. Cohn lamented: ‘But in most of our 
contexts, they’re priced out of reach.’ 
Leena Menghaney, Manager of MSF’s Access Campaign in India, commented: ‘There 
are millions of people without access to treatment, and many of those on treatment 
need to be switched to newer regimens.’ She observed: ‘If we are to get more 
people on treatment now, countries need to overcome patent barriers that 
undermine affordable access to drugs.’ MSF’s annual drug pricing report, Untangling 
the Web of Antiretroviral Price Reductions, revealed the problems with drug pricing. 
There has also been similar controversies in relation to access to medicines for 
other infectious diseases — such as tuberculosis. 
The Medicines Patent Pool has played a helpful role in encouraging access to 
essential medicines. The organisation was founded in 2010 by UNITAID to increase 
access to HIV treatment and help encourage co-operation between governments, 
pharmaceutical companies, and generic manufacturers. 
Just before the start of the Melbourne International AIDS Conference, the Medicines 
Patent Pool announced seven new sub-licensing agreements for the manufacture of 
generic HIV medicines, atazanavir (ATV) and dolutegravir (DTG).Greg Perry, Executive 
Director of the Medicines Patent Pool, observed: ‘With licences signed today, four 
new manufacturers are joining us to speed the availability of crucial medicines, ATV 
and DTG, to developing countries. This almost doubles our network of generic 
partners to ten companies’. He said ‘Increased generic competition will ultimately 
bring prices down and increase availability to allow national treatment programmes 
to treat many more people in their countries.’ 
The Australian Government under Tony Abbott has shown a strong interest in 
supporting medical research. The Medicines Patent Pool could play a useful role in 
disseminating the benefits of that research across the globe. 
UNITAID has expressed deep concerns about the impact of the Trans-Pacific 
Partnership upon access to essential medicines. The organisation has warned of the 
dangers of intellectual property provisions in the agreement: 
TRIPS-plus provisions also limit or undermine developing countries’ policy options for 
legislating and using TRIPS flexibilities, even though safeguards and flexibilities were 
included in the TRIPS Agreement to enable governments to protect public interests, 
including access to medicines. This has led to concerns that TRIPS-plus provisions 
in free trade agreements will undermine public health safeguards and objectives—
notably access to medicines. These concerns are particularly pertinent with regard 
to the negotiation of a Trans-Pacific Partnership Agreement, which has been 
positioned as a “model” for the 21st century—implying that the same or similar 
provisions are likely to appear in future trade agreements, including those involving 
developing countries. 
In addition to matters of intellectual property, UNITAID has been concerned that 
patent owners will use the investor-state dispute settlement mechanism to challenge 
measures related to access to essential medicines. The dispute between Eli Lilly and 
Canada highlights the dangers of the abuse of investment clauses. Moreover, there 
has also been concern about the impact of the Trans-Pacific Partnership on drug 
pricing. 
Dr Manica Balasegaram from MSF has similar concerns about the Trans-Pacific 
Partnership. He has stressed: ‘For the health and well-being of at least 800 million 
people, countries must reject these terms.’ The Australian Government should ensure 
that the trade and investment agreements that it negotiates do not undermine 
global action on access to essential medicines. 
Helen Clark — the administrator of the United Nations Development Programme, and 
the former New Zealand Prime Minister — told the Melbourne International AIDS 
Conference: 
HIV/AIDS can trap families, communities, and nations in poverty. The world won’t 
eradicate poverty without tackling this epidemic decisively.But AIDS is also 
increasingly a disease of inequalities and exclusion. In Sub-Saharan Africa, perhaps 
the best macroeconomic predictor of HIV prevalence now is the level of income 
inequality: the higher the inequality, the higher the rate of HIV. 
Helen Clark emphasized that ‘that leadership is vital if bad laws are to be changed’. 
She stressed that ‘we will support legislators to pass good laws which will turn the 
tide on HIV.’ Such legislative work is particularly important and critical in the field of 
intellectual property and access to essential medicines. 
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